Lyka Labs Ltd.
NSE: LYKALABS · Pharmaceuticals · sector
₹79.99NSE close 2026-10-26
Key numbers
Market cap₹289 cr
Price₹79.99
52w high / low₹99 / ₹44
P/E–Sector median 27.9x
P/B3.1xSector median 2.9x
Book value₹25.6
Dividend yield–Sector median 0.48%
ROE-9.2%Sector median 11.7%
ROCE-5.6%Sector median 12.3%
OPM-2.0%Sector median 14.0%
Debt / equity0.52xSector median 0.16x
EV/EBITDA–Sector median 18.6x
Interest cover-2.4x
Current ratio1.17x
Sales growth 3y+11.3%Sector median +9.6%
Profit growth 3y–Sector median +13.3%
PEG–
Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹1 cr vs borrowings ₹48 cr (FY26): borrowings are higher by ₹47 cr.
- Operating profit covered interest -2.4x in the last 12 months.
- No promoter shares are pledged.
- Operating cash flow was below net profit in 1 of the last 5 years (FY25).
- Net loss in 3 of the last 8 quarters.
- Revenue was higher than a year earlier in 1 of the last 4 quarters.
- Debtor days went from 89 (FY24) to 100 (FY26).
- No dividend in the last 5 financial years.
- Price ₹79.99 on 2026-10-26: -19.1% from the 52-week high, +81.4% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹166.91 · low ₹49.83
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 41 | 34 | 33 | 33 | 37 | 31 | 28 | 42 |
| EBITDA | 5 | 5 | 4 | 4 | -3 | 2 | -6 | 5 |
| OPM % | 12.0% | 15.4% | 12.2% | 11.2% | -6.9% | 5.4% | -23.0% | 10.8% |
| Other income | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 |
| Net profit | 2 | 3 | 2 | 1 | -3 | -0 | -8 | 2 |
| EPS (₹) | 0.58 | 0.75 | 0.49 | 0.25 | -0.94 | 0.00 | -2.13 | 0.57 |
| Revenue YoY | -10.9% | -9.1% | -16.2% | +28.1% | ||||
| Profit YoY | -260.0% | -105.6% | -529.9% | +107.0% |
Consolidated figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 194 | 93 | 111 | 138 | 128 | 138 |
| EBITDA | 95 | 9 | 15 | 18 | -3 | -3 |
| Net profit | 39 | -13 | -3 | 8 | -10 | -9 |
| EPS (₹) | 13.57 | -4.63 | -0.79 | 2.22 | -2.81 | -2.50 |
| Revenue growth | -52.0% | +19.5% | +24.6% | -7.3% | -2.6% | |
| Profit growth | -133.7% | – | – | -225.2% | -219.8% | |
| Dividend / share (₹) | – | – | – | – | – |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | +11.3% | +8.3% | -2.6% |
| Net profit | – | – | -219.8% |
| EPS | – | – | – |
| Share price | – | -22.7% (2y) | -12.5% |
Balance sheet
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Shareholders' equity | – | 45 | 68 | 104 | 92 |
| Borrowings | – | 72 | 57 | 38 | 48 |
| Cash & equivalents | – | 12 | 6 | 1 | 1 |
| Total assets | – | 152 | 157 | 176 | 175 |
| Fixed assets | – | 49 | 47 | 77 | 80 |
| Capital work in progress | – | 15 | 22 | 0 | 2 |
| Investments | – | 0 | 0 | 0 | 0 |
| Receivables | – | 20 | 27 | 43 | 35 |
| Inventory | – | 7 | 10 | 12 | 14 |
| Payables | – | 9 | 12 | 15 | 17 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash from operations | 79 | 9 | 2 | 2 | 5 |
| Cash from investing | 9 | 7 | -9 | -12 | -9 |
| Cash from financing | -64 | -22 | 2 | 5 | 4 |
| Capex | 8 | 8 | 9 | 16 | 11 |
| Free cash flow | 72 | 1 | -7 | -14 | -6 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ROE % | – | -28.9% | -3.8% | 7.7% | -10.9% |
| ROCE % | – | -1.1% | 3.2% | 9.5% | -6.0% |
| Debtor days | – | 79 | 89 | 114 | 100 |
| Inventory days | – | 68 | 78 | 82 | 99 |
| Payable days | – | 91 | 98 | 98 | 122 |
| Cash conversion cycle (days) | – | 56 | 69 | 98 | 77 |
| Working capital days | – | 46 | 43 | 55 | 27 |
Shareholding
| Holder | % (2026-09-30) |
|---|---|
| Promoters | 58.45% |
| FIIs | 0.15% |
| DIIs | 0.66% |
| of which Mutual funds | 0.01% |
| of which Insurance | 0.28% |
| Public (non-institutions) | 40.73% |
| Quarter | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters % | 58.10% | 58.16% | 58.16% | 58.16% | 58.16% | 58.16% | 58.45% | 58.45% |
| Promoter group | % |
|---|---|
| Ipca Laboratories Limited | 40.45% |
| Kunal Narendra Gandhi | 10.03% |
| Nehal Narendra Gandhi | 3.60% |
| Enai Trading and Investment PVT. Ltd | 3.04% |
| Pranay Godha | 0.83% |
| Alisha Kunal Gandhi | 0.14% |
| Sweta Shah | 0.11% |
| Ushma Ronak Shah | 0.09% |
| Lyka Generics Limited | 0.06% |
| Usha Godha | 0.03% |
| Premchand Godha | 0.03% |
| Neetu Godha | 0.03% |
| Bhawna Godha | 0.02% |
| Hiralaxmi Multitrade Private Limited | 0.00% |
| Public holders above 1% | % |
|---|---|
| Thermo Capital Private Limited | 1.91% |
25,885 shareholders. Pledged: 0.00% of promoter shares.
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| LYKALABS | ₹289 cr | – | 3.1x | -9.2% | -5.6% | -2.0% | +11.3% | – |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2024-08-01 | Other | Annual General Meeting |
| 2023-07-21 | Other | Annual General Meeting |
| 2022-07-21 | Other | Annual General Meeting |
| 2021-07-22 | Other | Annual General Meeting |
| 2020-09-16 | Other | Annual General Meeting |
| 2019-09-06 | Other | Annual General Meeting |
| 2018-09-19 | Other | Annual General Meeting |
| 2017-09-21 | Other | Annual General Meeting |
| 2016-09-19 | Other | Annual General Meeting |
| 2015-12-22 | Other | Annual General Meeting |
| 2014-12-22 | Other | Annual General Meeting |
| 2013-09-19 | Other | Annual General Meeting |
| 2012-09-26 | Other | Annual General Meeting |
| 2011-04-20 | Other | Annual General Meeting |
| 2010-03-22 | Other | Annual General Meeting |
| 2008-10-07 | Other | Annual General Meeting |
| 2007-08-16 | Other | Agm Bc Start Date Revised |
| 2006-05-04 | Other | Agm |
| 2005-03-17 | Other | Agm |
Documents
- Annual report FY26
- Annual report FY25
- Annual report FY24
- Annual report FY23
- Annual report FY22
- Announcements NSE filings
- Latest results (data file) XBRL
- Announcements BSE filings
Links go to the original files on the exchange website.
About the company
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | LYKALABS |
| BSE code | 500259 |
| ISIN | INE933A01014 |
| Face value | ₹10.0 |
| Incorporated | – |
| Website | – |
| Plants (India / abroad) | – |
Data built 2026-10-23 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.